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Abstract
Background: Surveillance in patients with previous polypectomy was underused in the Medicare population in 1994. This
study investigates whether expansion of Medicare reimbursement for colonoscopy screening in high-risk individuals has
reduced the inappropriate use of surveillance.
Methods: We used Kaplan-Meier analysis to estimate time to surveillance and polyp recurrence rates for Medicare
beneficiaries with a colonoscopy with polypectomy between 1998 and 2003 who were followed through 2008 for receipt of
surveillance colonoscopy. Generalized Estimating Equations were used to estimate risk factors for: 1) failing to undergo
surveillance and 2) polyp recurrence among these individuals. Analyses were stratified into three 2-year cohorts based on
baseline colonoscopy date.
Results: Medicare beneficiaries undergoing a colonoscopy with polypectomy in the 1998–1999 (n = 4,136), 2000–2001
(n = 3,538) and 2002–2003 (n = 4,655) cohorts had respective probabilities of 30%, 26% and 20% (p,0.001) of subsequent
surveillance events within 3 years. At the same time, 58%, 52% and 45% (p,0.001) of beneficiaries received a surveillance
event within 5 years. Polyp recurrence rates after 5 years were 36%, 30% and 26% (p,0.001) respectively. Older age ($ 70
years), female gender, later cohort (2000–2001 & 2002–2003), and severe comorbidity were the most important risk factors
for failure to undergo a surveillance event. Male gender and early cohort (1998–1999) were the most important risk factors
for polyp recurrence.
Conclusions: Expansion of Medicare reimbursement for colonoscopy screening in high-risk individuals has not reduced
underutilization of surveillance in the Medicare population. It is important to take action now to improve this situation,
because polyp recurrence is substantial in this population.
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Introduction
Individuals in whom adenomas have been detected are
considered to be at increased risk of developing colorectal cancer
(CRC), even after the adenomas have been removed [1]. These
high-risk individuals are therefore recommended to undergo
regular surveillance with colonoscopy (every five years if 1–2
adenomas smaller than 1 cm, every 3 years otherwise) [2].
Colonoscopic polypectomy and subsequent surveillance have been
estimated to reduce CRC incidence by 76–90% [1] and mortality
by 53% [3] in adenoma patients. In patients aged 50 years and
older, surveillance after adenoma removal is the single most
common indication for colonoscopy [4]. Two studies evaluating
the utilization of surveillance colonoscopy in adenoma patients
were recently published [5,6]. Both studies concluded that
surveillance colonoscopy was overused in low-risk subjects, while
concurrently being underused in higher-risk subjects.
The subjects in the aforementioned studies showing underuti-
lization were volunteers in the polyp prevention trial [5] and the
Prostate, Lung, Colorectal and Ovarian Cancer screening trial [6].
Volunteers in clinical trials are known to be more health conscious
and may consequently be more desirous and demanding of
frequent colonoscopy examinations. Their colonoscopy utilization
patterns may therefore not be representative of the general US
population and may underestimate the true problem of underuse
in the population, while at the same time overestimating overuse.
SEER-Medicare is generally representative of the elderly (65+
year-old) population and will as such provide better insight into the
PLOS ONE | www.plosone.org 1 November 2014 | Volume 9 | Issue 11 | e110937
under- and overuse of surveillance in the general population, at
least those aged 65 years and older, representing 67% of CRC [7].
A previous study of surveillance patterns in the Medicare
population showed that 25% of patients with previous polypec-
tomy did not undergo a surveillance event within 5 years [8]. At
the same time a high likelihood of polyp recurrence of more than
50% within 5 years was observed in those with surveillance,
underscoring the need for compliance with surveillance recom-
mendations. On the other hand, more than 50% of patients with
previous polypectomy received surveillance within the shortest
recommended surveillance interval of 3 years. This study was
conducted in a cohort of Medicare beneficiaries in 1994, before
coverage of colonoscopy screening for high-risk individuals
including adenoma patients was introduced in 1998. In the
current study, we investigated whether expansion of Medicare
reimbursement for colonoscopy screening in high-risk individuals
has affected the under- and overutilization of surveillance in this
population.
Methods
Data Source
The study population consisted of the 5% sample cohort of
Medicare beneficiaries without cancer who reside in SEER areas
obtained along with the SEER-Medicare database, a collaborative
effort of the National Cancer Institute, the SEER registries, and
the Centers for Medicare & Medicaid Services [9,10]. All non-
cancer SEER-Medicare enrollees (aged 66 and older) with full
coverage in Part A, Part B and no Health Maintenance
Organization (HMO) coverage for 24 consecutive months after
a claim for a colonoscopy with index polypectomy between 1998
and 2003 were included in the study and followed until December
31, 2008. To ensure that colonoscopies were being performed for
surveillance purposes, we excluded individuals with a cancer
diagnosis before or at baseline colonoscopy or two claims of any
one of the following diagnoses (for which colonoscopy may
constitute part of work up) indicated 12 months before polypec-
tomy: colitis and enteritis (International Classification of Diseases,
Ninth Revision, Clinical Modification (ICD-9) codes 009.0, 009.1,
555.1-555.2, 555.9, 556, 558), iron deficiency anemia (280.9),
chronic vascular insufficiency of intestine (557.1), unspecified
intestinal obstruction (560.9), diverticula (562.1), stenosis (569.2),
hemorrhage (569.3, 578.9), ulceration (569.41, 569.82), colostomy
and enterostomy complications (569.6), perforation (569.83), filling
defects (793.4), rupture (537.83–537.89), or other disorders of the
intestine (546.81–546.89, 569.85–569.86).
Analysis
To assess under- and over-utilization of surveillance in
individuals with polypectomy, we selected beneficiaries with at
least a baseline polypectomy between 1998 and 2003. Polypecto-
my claims were identified by searching outpatient and physician/
supplier claims files, using Health Care Common Procedure
Coding System (HCPCS) codes 45383, 45384, 45385; and ICD-9
codes 45.42, 45.43, 48.36. We used Kaplan-Meier analysis to
estimate the probability of undergoing a subsequent surveillance
event over time. A surveillance event was defined as follow-up by
colonoscopy (HCPCS codes G0105, G0121, 45378, 45380, 45383,
45384, 45385; and ICD-9 codes 45.23, 45.25, 45.42, 45.43,
48.36), sigmoidoscopy (HCPCS codes G0104, 45330, 45331,
45333, 45338, 45339, 45300–45320; and ICD-9 codes 45.24,
48.23, 48.24) or barium enema (HCPCS codes G0106, G0120,
74270, 74280). To investigate changes over time, for example
because of expansion of reimbursement in 2001, the analysis was
stratified by time of baseline colonoscopy: 1998–1999, 2000–2001
and 2002–2003. Individuals were included in a cohort if they had
a polypectomy within the selected time period. The baseline
colonoscopy was defined as the first colonoscopy with polypectomy
for an individual within the selected time period. As such, one
individual could contribute to all three cohorts, if this person had a
colonoscopy with polypectomy in each of the specified time
periods. However, an individual could only contribute once within
a cohort. Time was measured from the baseline colonoscopy to the
time of subsequent surveillance event or censoring because of:
1. End of enrollment of fee-for-service Part A or B, or enrollment
in HMO
2. Two diagnoses of any of the above-mentioned comorbidities
following index polypectomy
3. Death or
4. End of follow-up period (December 31, 2008)
To account for subjects brought back early for clinical concerns,
repeat colonoscopy, sigmoidoscopy or barium enema examina-
tions performed within 6 months of the baseline colonoscopy were
considered part of the baseline procedure and potential polypec-
tomies at those examinations were included with the baseline
results. Appendix S1 provides an overview of how patients
included in the study were followed over time and included in
the analyses.
Kaplan-Meier survival curves were used to estimate utilization
of surveillance in the Medicare population with previous
colonoscopy with polypectomy over time. Survival curves were
also used to estimate polyp recurrence rates for only those subjects
who had a surveillance event combined with a polypectomy. We
used 5-year survival estimates as the basis for comparison between
cohorts. In addition, we used Generalized Estimating Equations
(GEE) to estimate risk factors for failure to undergo surveillance
within 5 years in this population. We also used GEE to estimate
risk factors for subsequent polypectomy during surveillance in all
patients that had surveillance, accounting for patient-level
clustering as patients were allowed to contribute to more than
one cohort [11]. We could not use logistic regression because
observations were not completely independent due to repeated
measures for the same patient. Patient characteristics considered in
the model included age, race/ethnicity, gender, Charlson comor-
bidity score (including comorbidities developed after baseline
colonoscopy) [12], and urban versus rural status.
All analyses were performed using SAS software (version 9.2;
SAS Institute Inc, Cary, NC).
Sensitivity Analysis
We performed the following sensitivity analyses:
1. Inclusion of patients with polyps detected and removed at
(procto-) sigmoidoscopy (HCPCS: 45333, 45338, 45339,
45308, 45309, 45315, 45320)
2. Single inclusion of individuals in the cohort of their first
colonoscopy with polypectomy between 1998 and 2003.
(Individuals contributed to a single cohort)
3. Limiting the definition of a surveillance event to a colonoscopy
and
4. Including patients diagnosed with CRC from the SEER-
Medicare data between 1998-2003 who had at least 1
polypectomy more than 6 months before their diagnosis date.
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IRB approval
The Institutional Review Board of Morehouse School of
Medicine determined the study appropriate for exemption under
federal regulations.
Results
There were 3,538 Medicare beneficiaries with a polypectomy in
1998–1999, 4,136 in 2000–2001 and 4,655 in 2002–2003 fulfilling
our inclusion criteria. The characteristics of the population for
each of these cohorts are presented in Table 1. Approximately
55% of the patients in each cohort were women and the vast
majority lived in urban areas. The age and race distribution
differed between cohorts, with the 1998–1999 cohort having
relatively more white people and people between ages 66–69 years
than the 2000–2001 and 2002–2003 cohorts. Approximately 65%
of the population had or developed a Charlson comorbidity score
of 1 or more. Of the people that received a surveillance event,
around 98% received a colonoscopy.
Patients without a surveillance event were followed for a mean
period of 5.1–6.4 years, depending on cohort. Among the 6,985
patients with surveillance, 47% of surveillance events occurred
within 3 years, and 83% within 5 years. Mean follow-up until
surveillance was 3.2–3.4 years. A Kaplan-Meier probability curve
of surveillance utilization is presented in Figure 1. The cumulative
probability of a surveillance event within three years decreased
from 31.5% in the 1998–1999 cohort to 20.0% in the 2002–2003
cohort (p,0.001). At the same time, however, the cumulative
probability of a subsequent surveillance event within 5 years also
significantly decreased from 58% to 45% respectively (p,0.001).
Consequently, the probability of failure to undergo a surveillance
event within 5 years increased from 42% to 55% in this period.
GEE regression identified older age, female gender, later cohort
and high comorbidity as factors associated with failure to undergo
subsequent surveillance (Table 2). The highest odds ratios were
found for older age (increasing to 3.7 [95% CI: 3.0–4.4] for people
aged 85 years and older compared to people aged 66–69 years)
and severe comorbidity (increasing to 2.2 [95% CI: 2.0–2.4] for a
comorbidity score of 2+ compared to those without comorbidity)
(p,0.001). Rural status and race were not significantly associated
with failure to undergo subsequent colonoscopy.
The cumulative probability of polyp recurrence (Figure 2)
within 5 years also significantly decreased from 36% in the 1998–
1999 cohort to 26% in the 2002–2003 cohort (p,0.001).
However, these estimates are still high, showing that 58% of all
surveillance events within 5 years result in another polypectomy.
Among people with a surveillance event within 5 years, male
gender and early cohort were both associated with higher polyp
recurrence rates (Table 3), with male gender being the most
important one. The odds ratio for polyp recurrence in men
Table 1. Characteristics of study population, N (%).
Characteristics
1998–1999 cohort
N=3,538
2000–2001 cohort
N=4,136
2002–2003 cohort
N=4,655 Total N=10,852
Sex
Female 1,955 (55.3) 2,353 (56.9) 2,505 (53.8) 6,104 (56.3)
Male 1,583 (44.7) 1,783 (43.1) 2,150 (46.2) 4,748 (43.8)
Age¥
66–69 639 (18.1) 426 (10.3) 297 (6.4) 1,068 (9.8)
70–74 1,106 (31.3) 1,498 (36.2) 1,617 (34.7) 3,661 (33.7)
75–79 978 (27.6) 1,231 (29.8) 1,558 (33.5) 3,348 (30.9)
80–84 529 (15.0) 645 (15.6) 815 (17.5) 1,830 (16.9)
85+ 286 (8.1) 336 (8.1) 368 (7.9) 945 (8.7)
Race¥
White 3,003 (84.9) 3,443 (83.2) 3,830 (82.3) 9,022 (83.1)
Black 203 (5.7) 184 (4.5) 241 (5.2) 565 (5.2)
Other/Unknown* 332 (9.4) 509 (12.3) 584 (12.6) 1,265 (11.7)
Urban/Rural
Urban 3,477 (98.3) 4,075 (98.5) 4,570 (98.2) 10,668 (98.3)
Rural/Missing* 61 (1.7) 61 (1.4) 85 (1.8) 184 (1.7)
Charlson comorbidity score{
0 1,242 (35.1) 1,462 (35.4) 1,587 (34.1) 3,767 (34.7)
1 848 (24.0) 982 (23.7) 1,090 (23.4) 2,565 (23.6)
2 or more 1,448 (40.9) 1,692 (40.9) 1,978 (42.5) 4,520 (41.7)
If surveillance event, type of event
Barium enema 37 (1.6) 27 (1.0) 29 (1.3) 84 (1.4)
Colonoscopy 2,269 (97.5) 2,385 (97.9) 2,167 (97.5) 5,862 (97.5)
Sigmoidoscopy 21 (0.9) 24 (1.0) 26 (1.2) 64 (1.1)
¥Statistically significant difference (p,0.01) between 98–99, 00–01 and 02–03 cohort.
* There were 31 beneficiaries with unknown race, and 32 with missing urban/rural status.
{Including comorbidities developed within 5 years after baseline colonoscopy (or until censoring or event).
doi:10.1371/journal.pone.0110937.t001
Utilization of Surveillance after Polypectomy in Medicare
PLOS ONE | www.plosone.org 3 November 2014 | Volume 9 | Issue 11 | e110937
Figure 1. Kaplan-Meier estimates of probability of first surveillance event, stratified by cohort based on date of baseline
colonoscopy with polypectomy.
doi:10.1371/journal.pone.0110937.g001
Table 2. Odds ratio for failing to undergo a subsequent surveillance within 5 years after baseline colonoscopy among Medicare
beneficiaries with a colonoscopy with polypectomy between 1998 and 2003.
Risk Factor Estimate (CI)
Gender
Female 1 (referent)
Male 0.83 (0.77–0.90)¥
Age group
66–69 years 1 (referent)
70–74 years 1.13 (0.99–1.29)
75–79 years 1.48 (1.29–1.69)¥
80–84 years 1.80 (1.55–2.09)¥
85 years and older 3.65 (3.01–4.43)¥
Race
White 1 (referent)
Black 0.89 (0.75–1.06)
Other 0.99 (0.87–1.11)
Charlson comorbidity
0 1 (referent)
1 1.37 (1.24–1.52)¥
2+ 2.16 (1.97–2.36)¥
Cohort
1998–1999 1 (referent)
2000–2001 1.34 (1.22–1.47)¥
2002–2003 1.82 (1.66–1.99)¥
Urban/rural status
Urban 1 (referent)
Rural 0.95 (0.83–1.08)
Missing 0.55 (0.28–1.08)
¥Statistically significant (p,0.01).
doi:10.1371/journal.pone.0110937.t002
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compared to women was 1.4 (95% CI: 1.2–1.5). Age, race, rural
status and comorbidity status were not significantly associated with
polyp recurrence.
Sensitivity Analysis
Our results were robust for the sensitivity analyses we
performed. The 5-year probabilities of surveillance and polyp
recurrence stayed within 6%-points of the original estimates
(Table 4). Results were most influenced by limiting the inclusion of
individuals to their first polypectomy (probability of surveillance
event within 5 years decreased from 45% to 40% for the 2002–
2003 cohort), and inclusion of cancer cases (probability of
surveillance event increased from 58% to 64% for the 1998–
1999 cohort). In all sensitivity analyses, the risk factors for failure
to undergo surveillance and polyp recurrence from the GEE
models did not change (data not shown).
Discussion
This study shows that overuse of surveillance within 3 years
after a polypectomy decreased from 31.5% for Medicare
beneficiaries with a baseline polypectomy in 1998–1999 to 20%
in 2002–2003. However, at the same time underuse of surveillance
increased from 42% of Medicare beneficiaries with polypectomy
in 1998–1999 not receiving surveillance within 5 years to 55%
2002–2003. Especially, women, the elderly and people with
serious comorbidities were less likely to receive timely surveillance.
This study also shows that timely surveillance is important,
because approximately 60% of Medicare beneficiaries with
polypectomy and subsequent surveillance are found to have
another polyp. Polyp recurrence is especially high in the male
Medicare population.
Our results were robust to alternative inclusion criteria explored
in the sensitivity analyses. Limiting inclusion of individuals to their
first colonoscopy with polypectomy between 1998 and 2003
decreased the probability of surveillance the most (by 5%-points in
the 2002–2003 cohort). This was expected, because in this
sensitivity analysis, patients that undergo regular surveillance were
excluded from later cohorts, leaving patients with irregular
surveillance overrepresented. Including cancer cases and assuming
that all cancer diagnoses between 6 months and 5 years after
polypectomy were surveillance detected cancers, increased prob-
ability of surveillance the most, by 6%-points. It is unlikely that all
cancer cases were surveillance detected, but even under this
extreme assumption, the probability of surveillance did not exceed
64% and was still decreasing over time to 45% in the 2002–2003
cohort.
With the introduction of Medicare coverage of colonoscopy
screening for high-risk individuals in 1998, we anticipated an
increase in surveillance rates for this population but found
decreased rates. Possible explanations for this unexpected finding
include the growing recognition that surveillance in many settings
can and should be done less frequently (e.g. every 10 years in case
of 1 tubular adenoma) [13]. Furthermore, reimbursement of
colonoscopy screening may have triggered a different selection of
people to undergo colonoscopy. In the early years, our study
probably consisted mostly of high-risk patients with a family
history of CRC, while in later years more people without family
history (and lower likelihood of advanced adenomas) were likely
included in our study as Medicare expanded colonoscopy coverage
from only high-risk individuals in 1998 to all individuals in 2001.
Patients with family history are more likely to have advanced
adenomas and these two factors have been shown to synergistically
influence colonoscopy utilization [6]. The later cohort may not be
deemed as high-risk by treating physicians, compared with the
original set of people with symptoms and family history, and may
therefore not receive an intensive surveillance recommendation.
Another explanation for the decrease in surveillance rates might be
the improvement in the quality of colonoscopy, such as use of
high-definition endoscopes and use of split-dose preparation. As a
consequence of these techniques, treating physicians may be more
confident of having completely cleared the colon, recommending
longer surveillance intervals. In addition, higher quality colonos-
copy may have resulted in increased detection rates of diminutive
Figure 2. Kaplan-Meier estimates of polyp recurrence as indicated by surveillance polypectomy, stratified by cohort based on date
of baseline colonoscopy with polypectomy.
doi:10.1371/journal.pone.0110937.g002
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Table 3. Odds ratio for polyp recurrence as indicated by surveillance polypectomy among Medicare beneficiaries with a baseline
colonoscopy with polypectomy between 1998 and 2003 and a surveillance event within 5 years of that baseline colonoscopy.
Risk Factor Estimate (CI)
Gender
Female 1 (referent)
Male 1.38 (1.24–1.54)¥
Age group
66–69 years 1 (referent)
70–74 years 0.97 (0.82–1.15)
75–79 years 0.99 (0.83–1.17)
80–84 years 0.85 (0.69–1.05)
85 years and older 0.89 (0.65–1.20)
Race
White 1 (referent)
Black 0.77 (0.60–0.98)*
Other race 1.10 (0.93–1.31)
Charlson comorbidity
0 1 (referent)
1 1.09 (0.95–1.25)
2+ 1.33 (1.17–1.51)¥
Cohort
1998–1999 1 (referent)
2000–2001 0.92 (0.82–1.05)
2002–2003 0.88 (0.77–1.00)
Urban/rural status
Urban 1 (referent)
Rural 1.07 (0.89–1.30)
Missing 1.56 (0.63–3.88)
¥Statistically significant (p,0.01).
* Statistically significant (p,0.05).
doi:10.1371/journal.pone.0110937.t003
Table 4. Probability of first surveillance event and first polypectomy event within 5 years after baseline colonoscopy with
polypectomy among Medicare beneficiaries, stratified by cohort based on date of baseline colonoscopy with polypectomy –
results of sensitivity analyses (estimated using the Kaplan-Meier method).
Analysis* 1998–1999 cohort 2000–2001 cohort 2002–2003 cohort
Surveillance event
Base case1 58% 52% 45%
Include people with baseline sigmo2 60% 54% 46%
Single inclusion of individuals3 58% 49% 40%
Only colonoscopy surveillance4 57% 51% 44%
Include cancer cases5 64% 55% 45%
Polyp recurrence
Base case1 36% 30% 26%
Include people with baseline sigmo2 36% 31% 26%
Single inclusion of individuals3 36% 28% 22%
Only colonoscopy surveillance4 36% 30% 26%
Include cancer cases5 42% 33% 26%
*Results in the table refer to the following analyses: 1) original analysis; 2) Inclusion of patients with polyps detected and removed at (procto-) sigmoidoscopy; 3) Single
inclusion of individuals in the cohort of their first colonoscopy with polypectomy between 1998 and 2003; 4) Limiting the definition of a surveillance event to a
colonoscopy; 5) Including people from the SEER-Medicare data with a cancer diagnosis.
doi:10.1371/journal.pone.0110937.t004
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polyps. Diminutive polyps are more often non-neoplastic [14] and
people with non-neoplastic polyps are not recommended to
undergo regular surveillance [2]. Both explanations are supported
by the increasing number of people receiving baseline colonoscopy
with polypectomy (33% increase from 1998–1999 to 2002–2003)
likely influencing the composition of the population. However,
both also remain speculative and need further investigation.
Our estimates for the probability of inappropriate surveillance
within 3 years (20–31%) are considerably lower than those
reported in surveys among primary care physicians and endosco-
pists: in these surveys more than 50% of physicians recommended
surveillance within 3 years for people with a hyperplastic polyp or
small tubular adenomas only [15,16]. More recent estimates based
on medical chart review indicate that approximately 24% of
patients with hyperplastic polyps only were recommended to
undergo surveillance within 4–6 years and 35% of patients with
only small adenomas were recommended to return within 1–3
years [17], which is more in line with our estimates.
Our estimates for the probability of a surveillance event within 5
years for Medicare beneficiaries in the 2002–2003 cohort (45%)
are considerably lower than those found by Amonkar et al (74%)
[8] in a study cohort with index colonoscopies in 1994. Even
though our findings differ from those of Amonkar et al., our results
mirror those of Cooper at al. [18], whose study cohort reflects the
same timeframe. Cooper et al. found a decreasing trend in
surveillance utilization for more recent index colonoscopies. Thus,
practice pattern changes in more recent years are a very plausible
explanation. Possible explanations for the difference between our
results and those of Amonkar et al. are the inclusion of people with
prevalent polyps (i.e. a diagnosis of colorectal polyp before the
baseline colonoscopy) in Amonkar’s study and the exclusion of
individuals with gastrointestinal comorbidities for which colonos-
copy may constitute part of standard work up in our study. Our
findings are also consistent with findings from studies of
surveillance of adenoma patients in other health care settings.
Laiyemo et al. found a probability of a surveillance colonoscopy in
adenoma patients of 59.7% after a mean follow-up time of 5.9
years [5]. In the study by Schoen, surveillance probabilities after 5
years varied from 46.7% to 58.5% depending on the number and
type of adenomas found [6].
Risk factors for failure to receive subsequent surveillance are
also the ones associated with the lowest polyp recurrence rates:
later cohort and women. The lower polyp recurrence in later
cohorts can be explained by higher failure rates to undergo a
surveillance event. Interestingly age was not found to be a
predictor for polyp recurrence, while older age has been
consistently found to be an independent predictor for (advanced)
adenoma recurrence [19,20]. When age is investigated as a
potential risk factor, age is often dichotomized into younger than
60 and 60 years and older [20]. The fact that all individuals in our
study were into the latter category, might explain why we did not
see an age effect. Amonkar et al found polyp recurrence to
decrease with the age of the patient in Medicare [8]. They
suggested that frailty of the patient might play a role, and that
physicians suggest less aggressive treatments for patients in the
oldest age groups, because of increased risk of complications [21].
It has been suggested that removal of diminutive polyps could be
foregone, especially in older individuals as death from other causes
is likely to occur before these polyps become invasive tumors [22].
Several limitations are noteworthy. First, this study is based on
administrative data that were not collected for research purposes.
As a consequence, the data may contain errors due to billing and
coding. However, a study investigating the accuracy of Medicare
claims for measuring colorectal endoscopy use concluded that
Medicare claims can provide accurate information on whether a
patient has undergone colorectal endoscopy and may be more
complete than physician medical records [9]. A second study
investigating the accuracy of Medicare claims for identifying
findings and procedures performed during colonoscopy concluded
that Medicare claims have high sensitivity and specificity for polyp
detection, biopsy, and polypectomy at colonoscopy [23].
Second, it cannot be distinguished from Medicare data whether
subsequent colorectal examinations were performed for surveil-
lance purposes or for clinical reasons. This was also confirmed by
Schenck et al., suggesting that researchers who use Medicare
claims to assess rates of colorectal testing should include both
screening and diagnostic endoscopy procedures in their analyses
[9]. In this analysis, we included both types of procedures as
recommended, but we tried to exclude colorectal examinations for
clinical reasons by excluding people with comorbidities prior to
baseline colonoscopy that may require repeat colonoscopies for
reasons other than adenoma findings. As a result of that exclusion,
the population in this study will be somewhat healthier than the
average Medicare population. Third, our study only includes
patients enrolled in fee-for-service and not HMO. HMO patients
are shown to have higher stage at diagnosis for CRC, which may
indicate lower utilization since 2000 [24].
Fourth and most importantly, Medicare claims data lack
information on clinical polyp characteristics such as number of
polyps and size and histology of the polyps removed. As a result
not all beneficiaries in our cohorts may have actually had an
adenoma removed, but could also have had a non-adenomatous
polyp removed. Surveillance exams are not recommended for
people with these types of polyps [2], and we may have therefore
underestimated the probability of timely surveillance in our
analysis. In several studies in an average-risk (screening) popula-
tion, approximately half of people with polyps have been found to
have non-adenomatous polyps only [14,25,26]. In our study
approximately 50% of patients with polypectomy did not receive
surveillance. In theory, these could all be individuals with non-
adenomatous polyps only, and then the probability of timely
surveillance would actually be near-perfect. Given the careful
sensitivity analyses performed and the consistencies between our
estimated surveillance probabilities and that of other community-
based studies [5,6], near-perfect surveillance is unlikely.
In conclusion, our study shows that expansion of Medicare
reimbursement for colonoscopy screening in high-risk individuals
in 1998 has not reduced the underutilization of surveillance in the
Medicare population. Surveillance rates after polypectomy have
further declined between 1998 and 2003. Measures should be
taken to increase surveillance uptake, because polyp recurrence is
substantial in this population.
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